LAVA Therapeutics N.V. (LVTX)

NL — Healthcare Sector
Peers: ABOS  ANEB  CADL  EWTX  FNCH  HOWL  IKNA  KZR  NUVB  PHVS 

Automate Your Wheel Strategy on LVTX

With Tiblio's Option Bot, you can configure your own wheel strategy including LVTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol LVTX
  • Rev/Share 0.1856
  • Book/Share 0.9588
  • PB 1.5958
  • Debt/Equity 0.0121
  • CurrentRatio 6.7316
  • ROIC -0.4596

 

  • MktCap 40247109.0
  • FreeCF/Share -0.6105
  • PFCF -2.4516
  • PE -1.4674
  • Debt/Assets 0.0044
  • DivYield 0
  • ROE -0.8668

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade LVTX Leerink Partners Outperform Market Perform $11 $2 Dec. 12, 2024
Downgrade LVTX JMP Securities Mkt Outperform Market Perform -- -- Dec. 11, 2024

News

About LAVA Therapeutics N.V. (LVTX)

  • IPO Date 2021-03-26
  • Website https://www.lavatherapeutics.com
  • Industry Biotechnology
  • CEO Stephen Allen Hurly
  • Employees 34

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.